Altamira Therapeutics (CYTO) Company Presentation summary

Company overview and technology platform

• Proprietary RNA delivery platforms (OligoPhore, Semaphore, CycloPhore) enable efficient, extrahepatic delivery of siRNA, mRNA, and circRNA using 21-amino acid peptide nanoparticles.

• Technology achieves targeted delivery, strong endosomal escape (10x over LNPs), and avoids immune response or organ toxicity in preclinical models.

• Platform is positioned as a 'picks and shovels' strategy, with initial collaborations and out-licensing to pharma and biotech partners.

• RNA therapeutics market is rapidly expanding, with high growth in mRNA and siRNA segments and active M&A/licensing activity.

Flagship programs and pipeline

• Two lead programs: AM-401 (KRAS-driven cancers) and AM-411 (rheumatoid arthritis), both targeting IND submissions in 2026.

• AM-401 targets multiple KRAS mutations in pancreatic, colorectal, and lung cancers, offering polyvalent coverage and reduced resistance compared to small molecules.

• AM-411 targets NF-κB in inflamed tissues for rheumatoid arthritis, aiming for fewer systemic side effects and less resistance.

• Preclinical data show significant tumor reduction and anti-inflammatory effects in animal models.

Business strategy and partnerships

• Focus on external collaborations and in-house programs, with technology demonstrated in 17 disease models and 30+ publications.

• Active business development, with first two collaborators signed for heart tissue regeneration and mRNA vaccine applications.

• Divestiture of legacy assets (Bentrio nasal spray, inner ear programs) to unlock value and provide non-dilutive funding.